AMR Action Fund looks to tackle antimicrobial resistance with first two investments — but does the money arrive too late?
The AMR Action Fund — backed by a handful of heavyweight pharma players including Pfizer, Eli Lilly, Merck, Johnson & Johnson, Boehringer Ingelheim and GlaxoSmithKline — has made its first two investments in the hopes of addressing the looming threat of antimicrobial resistance.
But according to CEO Henry Skinner, there’s plenty more to go around this year.
AMR has promised to invest over $100 million this year in companies developing antimicrobials that can overcome resistance, starting with Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.